The age-old wisdom that vitamin C can help reduce the incidence of colds recently had another set back in a study from Finland, published in Cochrane Database of Systemic Reviews at the end of January 2013.
The age-old wisdom that vitamin C can help reduce the incidence of colds recently had another set back in a study from Finland, published in Cochrane Database of Systemic Reviews at the end of January 2013.
A review of placebo-controlled trials looking at vitamin C and colds carried out since 1966 showed that while vitamin C does have a small, consistent effect on the duration of colds, there was no effect on the incidence. The only exception was in patients who had been exposed to short periods of extreme physical stress.
The study seems to put an end to the debate over vitamin C’s ability to reduce the number of colds that someone has. The researchers excluded any study that used a vitamin C daily dosage of less than 0.2 g.
According to researchers, the studies looking at the incidence of colds in community populations had a pooled risk ratio (RR) of 0.97 (95% CI; 0.94–1.00), which represents an insignificant risk reduction of 3%. In studies surveying subjects involved in extreme activities such as running a marathon, the RR was 0.48 (95% CI; 0.35–0.64), showing a statistically significant risk reduction of 52%.
Data from 31 studies focused on whether or not vitamin C reduced the length of colds and demonstrated that regular supplements helped reduce symptoms by 8% in adults and 14% in children. However, data from seven studies concerning therapeutic supplementation started after the beginning of a cold indicated no consistent effects on either duration or severity of the cold.
“Given the consistent effect of vitamin C on the duration and severity of colds in the regular supplementation studies, and the low cost and safety, it may be worthwhile for common cold patients to test on an individual basis whether therapeutic vitamin C is beneficial for them,” the authors stated.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.